Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-small Cell Lung Cancer Cell lines

Zhen CHEN; Zhiwei CHEN
August 2010
Chinese Journal of Lung Cancer;Aug2010, Vol. 13 Issue 8, p769
Academic Journal
Background and objective The epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab has been used widely in non-small cell lung cancer patients. The aim of this study is to explore the effect of lung cancer cells (A549, H460, H1299, SPC-A-1) which were treated by cetuximab in vitro. Methods We studied the effects of increasing concentrations of cetuximab (1 nmol/L-625 nmol/L) in four human lung cancer cell lines (A549, SPC-A-1, H460, H1229). CCK8 measured the inhibition of cell proliferation in each group. A549, SPC-A-1 were marked by PI and the statuses of apoptosis were observed. Western blot were used to detect the proliferation-related signaling protein and apoptosis-related protein in A549. Results The treatment with cetuximab resulted in the effect on cell proliferation and apoptosis in a time- and dose-dependent manner. The expression of activated key enzymes (p-AKT, p-EGFR, p-MAPK) in EGFR signaling transduction pathway were down-regulated more obviously. Conclusion Cetuximab is an effective targeted drug in the treatment of lung cancer cell lines, tissues, most likely to contribute to the inhibition of key enzymes in EGFR signaling transduction pathway.


Related Articles

  • Erlotinib. Muir, Victoria J.; Dhillon, Sohita // BioDrugs;2011, Vol. 25 Issue 3, p139 

    Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of processes involved in cancer growth and development, including cell migration, proliferation, angiogenesis, and...

  • Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan. Nagai, Hiroki; Tanaka, Shiro; Niimi, Miyuki; Seo, Nanae; Sasaki, Takahiko; Date, Hiroshi; Mishima, Michiaki; Yasuda, Hiroyasu; Yanagihara, Kazuhiro // International Journal of Clinical Oncology;Oct2011, Vol. 16 Issue 5, p560 

    Purpose: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) patients. Adverse drug reactions of erlotinib in Japanese, which may be very different from those in Caucasians because...

  • Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Sequist, Lecia V. // Oncologist;Mar2007, Vol. 12 Issue 3, p325 

    Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and...

  • Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. Giuseppe Altavilla; Carmela Arrigo; Maria Santarpia; Giuseppe Galletti; Giovanni Picone; Grazia Marabello; Chiara Tomasello; Vincenzo Pitini // Journal of Neuro-Oncology;Oct2008, Vol. 90 Issue 1, p31 

    Abstract  Brain metastases are a common occurrence and a major cause of mortality in non-small-cell lung cancer, with few systemic treatment options. Although targeting epidermal growth factor receptor-associated tyrosine kinase with erlotinib and gefitinib results in durable responses in...

  • Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Lixia Ju; Caicun Zhou // Cancer Cell International;2013, Vol. 13 Issue 1, p1 

    Although some patients are initially sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), resistance invariably develops. Therefore, it's very important to study the molecular mechanism of this resistance. In our previous study we found that integrin beta1 can...

  • Timeline: Gefitinib-a novel targeted approach to treating cancer. Herbst, Roy S.; Fukuoka, Masahiro; Baselga, José // Nature Reviews Cancer;Dec2004, Vol. 4 Issue 12, p956 

    Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated...

  • Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer. Tiseo, M.; Loprevite, M.; Ardizzoni, A. // Current Medicinal Chemistry - Anti-Cancer Agents;Mar2004, Vol. 4 Issue 2, p139 

    Lung cancer is the leading cause of death worldwide. Current treatment modalities, including chemotherapy, radiotherapy and surgery, provide only limited improvement in the natural course of this disease. Therefore, the development of new therapeutic strategies is highly awaited. This review...

  • Cetuximab: a new hope for advanced NSCLC. Karmali, S. // Thorax;Oct2009, Vol. 64 Issue 10, p907 

    The article focuses on a randomized study which investigates a monoclonal antibody against the epidermal growth factor receptor (EGFR), cetuximab, as a treatment option for advanced non-small cell lung cancers. The study randomly assigns patients to chemotherapy with cetuximab or chemotherapy...

  • Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.  // BMC Medicine;2012, Vol. 10 Issue 1, p28 

    The article presents a study analysing the combined effect of RNA interference targeting the epidermal growth factor receptor (EGFR) mRNA, and inactivation of EGFR signaling with different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab. It shows that EGFR knockdown...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics